These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21294307)

  • 21. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone and refractory hypertension: a prospective cohort study.
    Sartori M; Calò LA; Mascagna V; Realdi A; Macchini L; Ciccariello L; De Toni R; Cattelan F; Pessina AC; Semplicini A
    Am J Hypertens; 2006 Apr; 19(4):373-9; discussion 380. PubMed ID: 16580572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in the treatment of severe drug resistant hypertension.
    Lobodzinski SS
    Cardiol J; 2011; 18(6):707-11. PubMed ID: 22113765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistant hypertension: diagnosis and management.
    Papadopoulos DP; Papademetriou V
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):113-8. PubMed ID: 16891288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Levels of biologically active substances in the blood of patients resistant and nonresistant to antihypertensive therapy].
    Tabak'ian EA; Dmitriev VV; Masenko VP; Kukharchuk VV
    Ter Arkh; 1999; 71(3):62-7. PubMed ID: 10234770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
    J Hypertens; 1998 Feb; 16(2):127-37. PubMed ID: 9535138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistant hypertension in a tertiary care clinic.
    Yakovlevitch M; Black HR
    Arch Intern Med; 1991 Sep; 151(9):1786-92. PubMed ID: 1888244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial.
    Sato A; Watanabe S; Okubo S; Toi T; Doi T; Nakano H; Tada J; Aonuma K;
    Hypertens Res; 2010 Dec; 33(12):1264-71. PubMed ID: 20927115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistant hypertension: what to do after trying 'the usual'.
    Kaplan NM
    Geriatrics; 1995 May; 50(5):24-5, 29-30; 33 passim. PubMed ID: 7737525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.
    Leenen FH; Wilson TW; Bolli P; Larochelle P; Myers M; Handa SP; Boileau G; Tanner J
    Can J Cardiol; 1997 Oct; 13(10):914-20. PubMed ID: 9374947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nurse management for hypertension. A systems approach.
    Rudd P; Miller NH; Kaufman J; Kraemer HC; Bandura A; Greenwald G; Debusk RF
    Am J Hypertens; 2004 Oct; 17(10):921-7. PubMed ID: 15485755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pharmacist intervention on control of resistant hypertension.
    Morse GD; Douglas JB; Upton JH; Rodgers S; Gal P
    Am J Hosp Pharm; 1986 Apr; 43(4):905-9. PubMed ID: 3706334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].
    Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J
    Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistant hypertension revisited: a comparison of two university-based cohorts.
    Garg JP; Elliott WJ; Folker A; Izhar M; Black HR;
    Am J Hypertens; 2005 May; 18(5 Pt 1):619-26. PubMed ID: 15882544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Refractory hypertension].
    Os I; Eide IK; Westheim AS; Kjeldsen SE
    Tidsskr Nor Laegeforen; 1995 Feb; 115(6):723-4. PubMed ID: 7900136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension?
    Muxfeldt ES; Salles GF
    J Hypertens; 2008 May; 26(5):878-84. PubMed ID: 18398329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistant hypertension: who and how to evaluate.
    Acelajado MC; Calhoun DA
    Curr Opin Cardiol; 2009 Jul; 24(4):340-4. PubMed ID: 19395953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of patients with hypertension resistant to treatment].
    Girerd X; Hanon O
    Rev Prat; 1999 Mar; 49(5):527-31. PubMed ID: 10358403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.